
NYSE:BSX
This summary was created by AI, based on 10 opinions in the last 12 months.
Boston Scientific Corp (BSX) has seen a decline in its stock price, breaking previous support levels and experiencing a loss of momentum in organic growth. The company, known for its non-invasive heart instrumentation and medical devices, has been affected by high valuations and increased competition in the space, particularly from rivals like Medtronic (MDT) and Abbott (ABT). While the long-term prospects remain promising due to an aging population and demand for less invasive medical solutions, near-term performance has been disappointing. Analysts note that despite being a leader in the medical device field, currently it is not performing well, with many investors being advised to reconsider their positions. Overall, the consensus among experts suggests caution, with some viewing Boston Scientific as an attractive investment at the right price, while others recommend more secure alternatives.
An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.
(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.